• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Ahmed, H. (2021). The clinical relevance of inosine triphosphate pyrophosphohydrolase(Itpa) genotypes in pediatric acute lymphoblastic leukemia. ALEXMED ePosters, 3(2), 17-18. doi: 10.21608/alexpo.2021.66803.1131
Hassnaa Embarak Ahmed. "The clinical relevance of inosine triphosphate pyrophosphohydrolase(Itpa) genotypes in pediatric acute lymphoblastic leukemia". ALEXMED ePosters, 3, 2, 2021, 17-18. doi: 10.21608/alexpo.2021.66803.1131
Ahmed, H. (2021). 'The clinical relevance of inosine triphosphate pyrophosphohydrolase(Itpa) genotypes in pediatric acute lymphoblastic leukemia', ALEXMED ePosters, 3(2), pp. 17-18. doi: 10.21608/alexpo.2021.66803.1131
Ahmed, H. The clinical relevance of inosine triphosphate pyrophosphohydrolase(Itpa) genotypes in pediatric acute lymphoblastic leukemia. ALEXMED ePosters, 2021; 3(2): 17-18. doi: 10.21608/alexpo.2021.66803.1131

The clinical relevance of inosine triphosphate pyrophosphohydrolase(Itpa) genotypes in pediatric acute lymphoblastic leukemia

Article 86, Volume 3, Issue 2, June 2021, Page 17-18  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2021.66803.1131
View on SCiNiTO View on SCiNiTO
Author
Hassnaa Embarak Ahmed email
Department of clinical and chemical pathology
Abstract
Acute lymphoblastic leukemia (ALL) is a malignant lymphoid cells proliferation at early stage of differentiation, it is primarily a disease of children under six years of age ; approximately 80-85% are of precursor B-cell phenotype.
With improvements in diagnosis and treatment, overall cure rate for children with ALL reached 85% in the developed world. Multiple recent studies indicate that genetic polymorphisms play an influential role in childhood ALL susceptibility, treatment response and prognosis.
The purine analog mercaptopurine is a key medication for the successful treatment of childhood ALL, Inosine triphosphate pyrophosphatase (ITPA) is one of several enzymes whose job is to cleanse the nucleotide pool. It catalyze the pyrophosphohydrolysis of 6-thioITP and methylthioITP and prevents the accumulation of such potentially toxic compounds. Therefore, the end result is that the ITPase enzyme acts to reduce the amount of active forms of the 6-MP drug present in human cells.
Characterization of ITPA deficiency by genotyping for the most common inactivating single-nucleotide polymorphisms can prospectively identify patients at higher risk of mercaptopurine toxicity which can subsequently influence the outcome of the patients.
Keywords
Itpa; 6-mp; survival
Supplementary Files
download 0017 final-E-POSTER.pdf
Statistics
Article View: 180
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.